Media
Press Releases
July 1, 2026
Lupin Announces EMA Approval for NaMuscla® Expansion for Pediatric Indication with New Strengths
June 26, 2026
Lupin Receives Tentative Approval from U.S. FDA for Enzalutamide Tablets
June 17, 2026
Lupin Launches Azilsartan Medoxomil Tablets in the United States
June 8, 2026
Lupin Collaborates with ERN for Luforbec®(beclometasone/formoterol) pMDI Launch in Spain
June 5, 2026
Lupin Receives Approval from U.S. FDA for RanluspecTM (ranibizumab) Injection
June 3, 2026
Lupin and Natco Receive Approval from U.S. FDA for Eribulin Mesylate Injection
May 29, 2026
Lupin Receives Approval from U.S. FDA for Sodium Sulfate, Magnesium Sulfate, and Potassium Chloride Tablets
May 28, 2026
Lupin Shares Phase 1 Data on LNP8701 at the ASCO Annual Meeting 2026
May 22, 2026
Lupin Receives China Approval for Oseltamivir Phosphate Oral Suspension
Media
Rajalakshmi Azariah
Vice President & Global Head - Corporate Communications
rajalakshmiazariah@lupin.comElise Titan
Director, U.S. Communications
elisetitan@lupin.comSmart Guide
Close
CloseSearch Product
Global Privacy Control Detected
We have detected your Global Privacy Control (GPC) signal. In accordance with applicable privacy laws, we have automatically honored your preference and disabled all non-essential cookies and tracking.
Only necessary cookies required for the website to function are enabled.
Opt-Out Request Honored
We have respected your privacy preference. Your opt-out request through cookie settings or Global Privacy Control signal has been honored.